Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach-Reference-Cited by-同舟云学术

Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach

Published:2019-10-24 Issue:1 Volume:38 Page:181-193
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Boussios Stergios^ORCID,Karihtala Peeter,Moschetta Michele,Abson Charlotte,Karathanasi Afroditi,Zakynthinakis-Kyriakou Nikolaos,Ryan Jake Edward,Sheriff Matin,Rassy Elie,Pavlidis Nicholas

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00867-4.pdf

Reference64 articles.

1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296

2. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23:2605–2612

3. Jones P, Wilcoxen K, Rowley M, Toniatti C (2015) Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 58:3302–3314

4. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917

5. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

2. Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016–2023);Molecular Diversity;2024-07-20

3. PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database;Expert Opinion on Drug Safety;2024-07-08

4. Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report;Frontiers in Pharmacology;2024-06-17

5. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer;Chinese Journal of Natural Medicines;2024-05